Since first described in 1980, 1 nonalcoholic fatty liver disease (NAFLD) is defined as the
accumulation of hepatic fat, as evidenced by radiologic or histologic examination, in the …

This review summarizes our current understanding of nonalcoholic fatty liver disease
(NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a …

Introduction To evaluate the efficacy of empagliflozin compared to pioglitazone in patients
with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). Methods In this …

As of 2016, there is no evidence-based pathway to stratify the risk of chronic liver disease in
a general population setting. Non-invasive tests of liver fibrosis might provide a mechanism …

Abstract Background & Aims Non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes
mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular …

METHODS: We recruited 237 patients undergoing FibroTouch and liver biopsy within 2
weeks. The pathological findings of liver biopsy were scored by Nonalcoholic …

Background & Aims Transient elastography (TE) is a noninvasive technique used to
measure liver stiffness to estimate the severity of fibrosis. The range of liver stiffness …

OBJECTIVES: Although liver biopsy is the gold standard for determining the degree of liver
fibrosis, issues regarding its invasiveness and the small amount of liver tissue evaluated can …

Non-alcoholic fatty liver disease (NAFLD) represents the hepatic expression of the metabolic
syndrome and is the most prevalent liver disease. NAFLD is associated with liver-related …

Approximately 30% of the worldwide population has at least one risk factor for liver disease.
Identifying advanced liver disease before the occurrence of complications remains a difficult …